Ultragenyx Pharmaceuticals shares are trading higher after the company and Mereo BioPharma Group announced positive 14-month results from the Phase 2 portion of the ongoing Phase 2/3 Orbit study.
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx Pharmaceuticals shares are trading higher following the announcement of positive 14-month results from the Phase 2 portion of the ongoing Phase 2/3 Orbit study, in collaboration with Mereo BioPharma Group.
June 12, 2024 | 5:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx Pharmaceuticals shares are trading higher after the company and Mereo BioPharma Group announced positive 14-month results from the Phase 2 portion of the ongoing Phase 2/3 Orbit study.
The positive results from the Phase 2 portion of the Orbit study are likely to boost investor confidence in Ultragenyx Pharmaceuticals, leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100